Takumu Hasebe

Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor

Koji Sawada, Hidemi Hayashi, Shunsuke Nakajima et al. · Journal of Gastroenterology and Hepatology · 2019 · 55 citations

Daikenchuto (TU‐100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K

Takumu Hasebe, Nobuhiro Ueno, Mark W. Musch et al. · Pharmacology Research & Perspectives · 2016 · 38 citations · Full text

Butyrate and bioactive proteolytic form of Wnt-5a regulate colonic epithelial proliferation and spatial development

Kazuhiko Uchiyama, Toshio Sakiyama, Takumu Hasebe et al. · Scientific Reports · 2016 · 36 citations · Full text

Augmented hepatic <scp>T</scp>oll‐like receptors by fatty acids trigger the pro‐inflammatory state of non‐alcoholic fatty liver disease in mice

Koji Sawada, Takaaki Ohtake, Takumu Hasebe et al. · Hepatology Research · 2013 · 32 citations

Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature

Koji Sawada, Tatsuya Shonaka, Yuji Nishikawa et al. · Internal Medicine · 2019 · 29 citations · Full text

Successful Treatment, Immunology, Gastroenterology +18